With 1.64 million shares changed hands, the volume of the stock remained heavier than its average volume of 1.2 million shares. During the session, the Medical Care Facilities company that operates in wider Healthcare sector, reached to the highest price of $356.76 whereas the lowest price it dropped to was $345.92. The 52-week range on HCA shows that it touched its highest point at $417.14 and its lowest point at $226.48 during that stretch. It currently has a 1-year price target of $410.27. With its current market cap of 90.18 billion, HCA has annualized dividend of $2.58 while the current yield stands at 0.72%. HCA paid its most recent dividend on 1726444800, while the ex-dividend date for that was 1734048000. Beta for the stock currently stands at 1.67.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of HCA was down-trending over the past week, with a drop of -0.76%, but this was down by -7.85% over a month. Three-month performance dropped to -1.35% while six-month performance rose 10.61%. The stock gained 52.73% in the past year, while it has gained 31.53% so far this year. A look at the trailing 12-month EPS for HCA yields 22.28 with Next year EPS estimates of 24.77. For the next quarter, that number is 6.19. This implies an EPS growth rate of 16.12% for this year and 12.23% for next year. EPS is expected to grow by 12.00% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 12.21%.
Float and Shares Shorts:
At present, 265.54 million HCA shares are outstanding with a float of 182.21 million shares on hand for trading. On 2024-10-15, short shares totaled 2.86 million, which was 111.99999999999999 higher than short shares on 1726185600. In addition to Mr. Samuel N. Hazen as the firm’s CEO & Director, Mr. Jon Mack Foster serves as its Executive VP & COO.
Institutional Ownership:
Through their ownership of 0.65727997 of HCA’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-09-30, HCA reported revenue of $17487000000.0 and operating income of $2410000000.0. The EBITDA in the recently reported quarter was $3267000000.0 and diluted EPS was $4.88.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for HCA since 20 analysts follow the stock currently. There are 17 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 3 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With HCA analysts setting a high price target of 460.0 and a low target of 359.0, the average target price over the next 12 months is 410.45. Based on these targets, HCA could surge 29.2% to reach the target high and rise by 0.83% to reach the target low. Reaching the average price target will result in a growth of 15.29% from current levels.
Analysts have provided yearly estimates in a range of $23.25297 being high and $21.64932 being low. For HCA, this leads to a yearly average estimate of $22.12039. The surprise factor in the prior quarter was $4.85. Based on analyst estimates, the high estimate for the next quarter is $6.08 and the low estimate is $5.6. The average estimate for the next quarter is thus $5.79.
